Teon Therapeutics Entered into a Clinical Trial Collaboration with Merck to Evaluate TT-816 + Keytruda (pembrolizumab) for Solid Tumors
Shots:
- The companies collaborated to evaluate TT-816 (CB2 receptor antagonist) as monotx. or in combination with Merck’s Keytruda (anti-PD-1 therapy) in an ongoing P-I/II dose escalation & expansion study in ~200 patients who have not responded to SoC & with limited treatment options
- The P-I study will evaluate the safety, tolerability, PK, and preliminary clinical activity and determine a recommended dose of TT-816 & the P-II study will assess safety & preliminary efficacy
- Preclinical research revealed that TT-816 has distinct MoA that boosts T cell & NK cell antitumor immunity, prevents broad-based T cell exhaustion, synergizes antitumor effects with current immune checkpoint inhibitor therapies & encourages T cell infiltration into solid tumors
Ref: Businesswire | Image: Teon Therapeutics
Related News:- MSD’s Keytruda (pembrolizumab) Receives the NICE Recommendation for the Treatment of Triple-Negative Breast Cancer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
